---
schema_version: "secwatch.filing_event.v1"
accession: "0001293971-24-000046"
form_type: "8-K"
ticker: null
cik: "0001293971"
company_name: "bluebird bio, Inc."
filed_at: "2024-09-24T23:59:59+00:00"
generated_at: "2026-05-31T01:59:58.262719+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# bluebird bio cuts workforce 25%, targets 20% opex reduction and cash flow break-even in H2 2025

## Summary
- Restructuring reduces headcount by ~25% and cash operating expenses by ~20% when fully realized in Q3 2025.
- One-time cash charges of ~$3.7M for severance; stock-based compensation of $0.3M-$0.5M; most recorded in Q3 2024.
- Cash flow break-even target in H2 2025 requires ~40 drug product deliveries per quarter and additional capital.
- Year-to-date 41 patient starts; expects ~40 patient starts in Q4 2024 across three approved gene therapies.
- Restructuring substantially complete by Q1 2025; savings fully realized Q3 2025.

## SEC filing metadata
- accession: 0001293971-24-000046
- form_type: 8-K
- cik: 0001293971
- company_name: bluebird bio, Inc.
- filed_at: 2024-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000046/0001293971-24-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000046/blue-20240923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001293971-24-000046
- JSON: https://secwatch.observer/filing/0001293971-24-000046.json
- Plain text: https://secwatch.observer/filing/0001293971-24-000046.txt

## Key facts
- Restructurings & Charges
  bluebird bio, Inc. announced a restructuring with charges of approximately $3.7 million in cash expenditures for severance and employee termination-related costs (approximately 25% of its headcount).
  - Type: restructuring
  - Charge: approximately $3.7 million in cash expenditures for severance and employee termination-related costs
  - Headcount: approximately 25% of its headcount
  source text: The Company’s board of directors approved the Restructuring on September 23, 2024, following a comprehensive review of the Company’s operations. The Restructuring includes a reduction of the Company’s workforce by approximately 25% of its headcount. As a result of the Restructuring, the Company estimates that it will incur aggregate charges of approximately $3.7 million in cash expenditures for severance and employee termination-related costs to be paid out over multiple weeks through the end of the fiscal year ending December 31, 2024, as well as approximately $0.3 million - $0.5 million in stock-based compensation expense.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000046/0001293971-24-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.